In this research note, we provide a primer on how VC-backed companies within the biotechnology & pharmaceutical sector have performed, as well as discuss how VC investing has evolved from government grants to newer sources of capital. Given that venture funding is overwhelmingly the first stop biotech startups make when seeking capital, we believe a thorough analysis of this sector will allow investors to better understand the importance that VC plays in funding and accelerating revolutionary therapies into the clinic. We also provide an outlook on how VC-backed biotechs have been a flight to quality for many investors outside of the VC asset class, and how macroeconomic factors impact both private-backed and publicly held biotech & pharma companies.